Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $50.8252W HIGH $85.84
Volume
472.10 K
Value Traded
136.75 M
Short % Float
12.87%
Days to Cover
17.1
+4.71%Week
+6.83%1 Month
+15.48%3 Month
+29.55%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.80 B
EPS (TTM)
-0.27
P/E Ratio
-
Ent. Value
6.43 B
Total Shares
78.70 M
Float Shares
70.42 M
Insiders
10.52%
Institutions
103.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RDNT Catalyst Timeline
Dated clinical, regulatory and corporate events for RadNet, Inc.
Past FDA Catalysts and PDUFA Decisions
How RDNT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
RadNet, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RDNT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SWARTZ DAVID LDirector | Sell | -2,699 177,013 held | $53.89 | 06/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RDNT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 2.6 % (8.3 %) | 298.91 M | 4.85 M | 13.11% ( 561.96 K) |
RDNT Institutional Ownership Trends
RDNT Short Interest
Shares sold short, counted twice a month.
12.87%
Short % of Float
of tradable shares sold short
9.1M
Shares Sold Short
-3.2% vs prior count
17.1 Very high
Days to Cover
trading days of normal volume to buy every short share back
530.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RDNT ranks across every disease it competes in
Competitive Position is a premium feature
See how RDNT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRDNT News
-RDNT
Oct 29, 2026▲ +0.2%today
RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call
RadNet, Inc. announced a conference call scheduled for November 9, 2026, to discuss its third quarter financial results. The call will take place at 7:30 a.m. Pacific Time and will be accessible to investors via phone and webcast. RadNet is recognized as a leading provider of diagnostic imaging services in the U.S.
Read more →-RDNT
Oct 26, 2026▲ +0.2%today
RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.
RadNet, Inc. announced its agreement to acquire ONRAD, Inc., enhancing its radiology services. The acquisition is projected to contribute $190 million to $200 million in revenue and $60 million to $65 million in adjusted EBITDA in its first year. This move positions RadNet to better meet the increasing demand for imaging services across various healthcare settings.
Read more →-RDNT
Oct 1, 2026RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals
RadNet has partnered with WIN-NextGen to introduce students and young adults to careers in medical imaging. This initiative aims to address the workforce shortage in radiology by providing mentorship, digital learning experiences, and hands-on opportunities. The program targets learners aged 12 to 24 in Maryland, D.C., and Virginia, with plans for expansion to include internships and scholarships.
Read more →-RDNT
Sep 9, 2026RadNet to Host Free Prostate Cancer Webinar on September 19, 2026
RadNet, Inc. will host a free webinar on September 19, 2026, focusing on prostate cancer awareness. The event will feature discussions led by medical experts and a prostate cancer survivor, covering topics such as risk factors, screening, and treatment options. Attendees can ask questions during a live Q&A session, promoting better understanding of prostate health.
Read more →-RDNT
Sep 9, 2026RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026
RadNet, Inc. announced that its Executive Vice President and CFO, Mark Stolper, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16th, 2026. The presentation will take place at 07:45 a.m. Eastern Time and will be available via webcast. RadNet is recognized for its extensive network of outpatient imaging centers across the U.S.
Read more →-RDNT
Sep 8, 2026RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
RadNet, Inc. announced that Dr. Greg Sorensen will present at the Jefferies Healthcare Services Conference on September 15, 2026. The presentation will take place at 9:10 a.m. Central Time. The event will be available via live and archived webcasts on RadNet's website.
Read more →-RDNT
Aug 9, 2026▲ +6.8%on this news
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
RadNet reported strong financial results for Q2 2026, achieving record revenue of $622.7 million, a 25% increase from the previous year. The Digital Health segment also saw significant growth, with revenue up 56.5%. However, the Adjusted EBITDA for the Digital Health segment decreased, reflecting ongoing investments. The company has revised its 2026 financial guidance upwards, anticipating continued strong performance.
Read more →-RDNT
Jul 22, 2026RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
RadNet, Inc. has announced a conference call scheduled for August 10, 2026, to discuss its second quarter financial results for the year. The call will be accessible to investors via phone and webcasts. RadNet is recognized as a leading provider of diagnostic imaging services across the United States.
Read more →-RDNT
Jun 25, 2026DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
DeepHealth, a subsidiary of RadNet, has received FDA 510(k) clearances for two new functionalities in its Breast Suite. The Breast Arterial Calcification Assessment tool aids in identifying cardiovascular risks during mammograms, while Mammo Dx integrates prior exam data to enhance cancer detection. Both features are now commercially available in the U.S.
Read more →-RDNT
Jun 10, 2026DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
DeepHealth, a subsidiary of RadNet, launched Reporting Pro, an AI-powered radiology reporting solution. This platform integrates speech recognition and clinical AI to streamline report generation. With its commercial rollout, it aims to address the projected radiologist shortage and improve reporting efficiency. The solution is now available in the U.S. and U.K., with plans for further expansion.
Read more →-RDNT
Jun 10, 2026RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%
RadNet, Inc. has secured a $250 million incremental term loan to support its growth initiatives. The loan, part of an amendment to its existing credit agreement, will mature in 2031 and is expected to finance acquisitions and expansions. Additionally, RadNet has successfully reduced the interest rates on its credit facilities by 0.25%, enhancing its financial position.
Read more →-RDNT
Jun 3, 2026RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities
RadNet, Inc. announced plans to secure a $200 million incremental term loan to support its strategic growth initiatives. The funds will be used for acquisitions, organic expansion, and partnerships. The loan is expected to mature in April 2031, coinciding with the existing term loan. The company aims to finalize the transaction by mid-June 2026, pending market conditions.
Read more →-RDNT
May 28, 2026RadNet to Host Men's Health Webinar on June 13, 2026
RadNet, Inc. will host a free webinar on June 13, 2026, focusing on men's health issues, including coronary artery disease, prostate cancer, and lung cancer. The event will feature expert presentations and a live Q&A session, aiming to educate attendees on risk factors and the importance of early detection. This initiative aligns with National Men's Health Month, emphasizing preventive care.
Read more →-RDNT
May 10, 2026RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow
RadNet, Inc. reported a record first quarter for 2026, with total revenue increasing by 22.1% to $575.6 million compared to the previous year. The company also saw a 36.3% rise in Adjusted EBITDA, driven by growth in advanced imaging procedures. Despite some challenges, including a decrease in Digital Health Adjusted EBITDA, RadNet has revised its financial guidance for the year upwards, reflecting strong operational trends.
Read more →-RDNT
Apr 30, 2026RadNet and Trinity Health’s Saint Alphonsus Health System Launch a Multi-Site Joint Venture in Boise, Idaho, to Include a Broad Technology Deployment of DeepHealth Solutions
RadNet has formed a joint venture with Saint Alphonsus Health System, acquiring a majority stake in Intermountain Medical Imaging in Boise, Idaho. This partnership will enhance outpatient imaging services through advanced AI solutions from DeepHealth. The venture is projected to generate approximately $30 million in annual revenue for RadNet.
Read more →-RDNT
Apr 28, 2026RadNet, Inc. Announces Date of its First Quarter 2026 Financial Results Conference Call
RadNet, Inc. has announced a conference call scheduled for May 11, 2026, to discuss its first quarter financial results for the year. The call will take place at 7:30 a.m. PT and will be accessible to both domestic and international investors. Additionally, an archived replay of the call will be available for those unable to attend live.
Read more →-RDNT
Mar 17, 2026RadNet, Inc. to Present Today at the KeyBanc Capital Markets Healthcare Forum
RadNet, Inc. announced that CFO Mark Stolper will present at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026. The presentation is scheduled for 4:30 p.m. Eastern Time. RadNet is recognized for its extensive network of diagnostic imaging services across multiple states.
Read more →-RDNT
Mar 11, 2026RadNet, Inc. to Present at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12th
RadNet, Inc. will present at the 28th Annual Barclays Global Healthcare Conference on March 12, 2026. Mark Stolper, the CFO, will speak at 8:00 a.m. Eastern Time. The company is recognized for its extensive network of diagnostic imaging services across multiple states.
Read more →-RDNT
Mar 4, 2026DeepHealth Unveils Industry’s Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026
DeepHealth has launched an extensive portfolio of AI solutions for clinical imaging at ECR 2026, enhancing capabilities across various modalities including MR, CT, and X-ray. The acquisition of Gleamer strengthens its position in routine imaging and diagnostic care. The new tools are designed to improve patient outcomes and operational efficiency in healthcare systems.
Read more →-RDNT
Mar 4, 2026RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS
RadNet, Inc. is hosting a conference call on March 5, 2026, to discuss its recent acquisition of Gleamer SAS and its Digital Health strategy. Investors will have the chance to hear from executive management and ask questions. RadNet continues to strengthen its position in the diagnostic imaging market with innovative AI solutions.
Read more →About RadNet, Inc.
Headquarters1510 COTNER AVE, LOS ANGELES, CA, 90025
BIOPHARMAWATCH ELITE PLUS
Trade the next RDNT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime